JP2015520238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520238A5 JP2015520238A5 JP2015518539A JP2015518539A JP2015520238A5 JP 2015520238 A5 JP2015520238 A5 JP 2015520238A5 JP 2015518539 A JP2015518539 A JP 2015518539A JP 2015518539 A JP2015518539 A JP 2015518539A JP 2015520238 A5 JP2015520238 A5 JP 2015520238A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound
- stereoisomer
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 50
- 150000003839 salts Chemical class 0.000 claims 37
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 125000001072 heteroaryl group Chemical group 0.000 claims 12
- 125000000623 heterocyclic group Chemical group 0.000 claims 12
- 201000000980 schizophrenia Diseases 0.000 claims 11
- 208000028017 Psychotic disease Diseases 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000003342 alkenyl group Chemical group 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 9
- 125000004404 heteroalkyl group Chemical group 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 8
- 125000001475 halogen functional group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims 6
- 208000010877 cognitive disease Diseases 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 6
- 150000003573 thiols Chemical class 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 5
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 125000004122 cyclic group Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 208000022821 personality disease Diseases 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 208000019022 Mood disease Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 208000024714 major depressive disease Diseases 0.000 claims 2
- 208000004296 neuralgia Diseases 0.000 claims 2
- 208000021722 neuropathic pain Diseases 0.000 claims 2
- 230000000698 schizophrenic effect Effects 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 208000017194 Affective disease Diseases 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003805 Autism Diseases 0.000 claims 1
- 208000020706 Autistic disease Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000024254 Delusional disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000020401 Depressive disease Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018612 Gonorrhoea Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033864 Paranoia Diseases 0.000 claims 1
- 208000027099 Paranoid disease Diseases 0.000 claims 1
- 208000027465 Psychotic Affective disease Diseases 0.000 claims 1
- 206010061921 Psychotic disorder due to a general medical condition Diseases 0.000 claims 1
- 208000005793 Restless legs syndrome Diseases 0.000 claims 1
- 206010070834 Sensitisation Diseases 0.000 claims 1
- 208000019568 Shared Paranoid disease Diseases 0.000 claims 1
- 208000028810 Shared psychotic disease Diseases 0.000 claims 1
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims 1
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 1
- 208000021017 Weight Gain Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000016571 aggressive behavior Effects 0.000 claims 1
- 238000013019 agitation Methods 0.000 claims 1
- 125000003368 amide group Chemical group 0.000 claims 1
- -1 amino, imino Chemical group 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 230000003542 behavioural effect Effects 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 201000003104 endogenous depression Diseases 0.000 claims 1
- 230000002964 excitative effect Effects 0.000 claims 1
- 208000001786 gonorrhea Diseases 0.000 claims 1
- 201000001421 hyperglycemia Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 230000014759 maintenance of location Effects 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 1
- 125000003367 polycyclic group Chemical group 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 208000012672 seasonal affective disease Diseases 0.000 claims 1
- 230000008313 sensitization Effects 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 201000009032 substance abuse Diseases 0.000 claims 1
- 231100000736 substance abuse Toxicity 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 0 C*c1n[n](*I)c(C)c1C Chemical compound C*c1n[n](*I)c(C)c1C 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261661710P | 2012-06-19 | 2012-06-19 | |
| US61/661,710 | 2012-06-19 | ||
| PCT/US2013/046483 WO2013192273A1 (en) | 2012-06-19 | 2013-06-19 | Heteroaryl compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017174559A Division JP6422542B2 (ja) | 2012-06-19 | 2017-09-12 | ヘテロアリール化合物及びその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520238A JP2015520238A (ja) | 2015-07-16 |
| JP2015520238A5 true JP2015520238A5 (enExample) | 2016-07-28 |
| JP6236439B2 JP6236439B2 (ja) | 2017-11-22 |
Family
ID=49769319
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015518539A Expired - Fee Related JP6236439B2 (ja) | 2012-06-19 | 2013-06-19 | ヘテロアリール化合物及びその使用方法 |
| JP2017174559A Expired - Fee Related JP6422542B2 (ja) | 2012-06-19 | 2017-09-12 | ヘテロアリール化合物及びその使用方法 |
| JP2018194979A Expired - Fee Related JP6786566B2 (ja) | 2012-06-19 | 2018-10-16 | ヘテロアリール化合物及びその使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017174559A Expired - Fee Related JP6422542B2 (ja) | 2012-06-19 | 2017-09-12 | ヘテロアリール化合物及びその使用方法 |
| JP2018194979A Expired - Fee Related JP6786566B2 (ja) | 2012-06-19 | 2018-10-16 | ヘテロアリール化合物及びその使用方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US9505751B2 (enExample) |
| EP (1) | EP2861596B1 (enExample) |
| JP (3) | JP6236439B2 (enExample) |
| KR (1) | KR20150021120A (enExample) |
| CN (1) | CN104583210B (enExample) |
| AU (1) | AU2013277258B2 (enExample) |
| BR (1) | BR112014031798A2 (enExample) |
| CA (1) | CA2874180A1 (enExample) |
| IL (1) | IL235909A (enExample) |
| IN (1) | IN2015DN00345A (enExample) |
| MX (1) | MX374323B (enExample) |
| NZ (1) | NZ702239A (enExample) |
| RU (1) | RU2644558C2 (enExample) |
| SG (1) | SG11201408178TA (enExample) |
| WO (1) | WO2013192273A1 (enExample) |
| ZA (1) | ZA201408856B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI828027B (zh) | 2016-03-28 | 2024-01-01 | 美商英塞特公司 | 作為tam抑制劑之吡咯并三嗪化合物 |
| WO2020065583A1 (en) | 2018-09-28 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| US12134616B2 (en) | 2018-10-23 | 2024-11-05 | Basf Se | Tricyclic pesticidal compounds |
| CN110386897A (zh) * | 2019-08-15 | 2019-10-29 | 上海毕得医药科技有限公司 | 一种4-氟-3-甲基吡啶-2-胺的合成方法 |
| MX2022006370A (es) | 2019-11-25 | 2022-09-07 | Amgen Inc | Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso. |
| EP4136086A1 (en) | 2020-04-14 | 2023-02-22 | Basf Se | Tricyclic pesticidal compounds |
| CN119707962B (zh) * | 2024-12-14 | 2025-11-11 | 中山大学 | 一类氮杂四元环连接的吡唑并吡啶类化合物或其药学上可接受的盐及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2274712B1 (es) * | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| EP2227472A1 (en) | 2007-11-30 | 2010-09-15 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
| TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物 |
| EP2318410A2 (en) * | 2008-07-09 | 2011-05-11 | Envivo Pharmaceuticals, Inc. | New small-molecule pde-10 inhibitors |
| TWI485151B (zh) * | 2009-12-17 | 2015-05-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族苯基咪唑衍生物 |
| TWI487705B (zh) * | 2009-12-17 | 2015-06-11 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物 |
| TWI481607B (zh) * | 2009-12-17 | 2015-04-21 | Lundbeck & Co As H | 作為ｐｄｅ１０ａ酵素抑制劑的２－芳基咪唑衍生物 |
| WO2011150156A2 (en) | 2010-05-26 | 2011-12-01 | Sunovion Pharmaceuticals Inc. | Heteroaryl compounds and methods of use thereof |
| US20130203756A1 (en) * | 2010-10-29 | 2013-08-08 | Jamie L. Bunda | Isoindoline pde10 inhibitors |
| JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
| JP6106603B2 (ja) * | 2011-01-11 | 2017-04-05 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
| WO2012147890A1 (ja) * | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | 新規アゾール誘導体 |
| US8592423B2 (en) * | 2011-06-21 | 2013-11-26 | Bristol-Myers Squibb Company | Inhibitors of PDE10 |
| MX2014000452A (es) * | 2011-07-15 | 2014-03-21 | Shionogi & Co | Derivados de azabencimiazol que tiene actividad activadora de la proteina cinasa activada monofosfato de denosina (ampk). |
| WO2013052526A1 (en) * | 2011-10-06 | 2013-04-11 | Merck Sharp & Dohme Corp. | Triazolyl pde10 inhibitors |
-
2013
- 2013-06-19 WO PCT/US2013/046483 patent/WO2013192273A1/en not_active Ceased
- 2013-06-19 MX MX2014014751A patent/MX374323B/es active IP Right Grant
- 2013-06-19 CN CN201380032220.6A patent/CN104583210B/zh not_active Expired - Fee Related
- 2013-06-19 EP EP13806923.2A patent/EP2861596B1/en not_active Not-in-force
- 2013-06-19 CA CA2874180A patent/CA2874180A1/en not_active Abandoned
- 2013-06-19 US US14/409,866 patent/US9505751B2/en not_active Expired - Fee Related
- 2013-06-19 KR KR1020157001398A patent/KR20150021120A/ko not_active Ceased
- 2013-06-19 NZ NZ702239A patent/NZ702239A/en not_active IP Right Cessation
- 2013-06-19 IN IN345DEN2015 patent/IN2015DN00345A/en unknown
- 2013-06-19 BR BR112014031798A patent/BR112014031798A2/pt not_active Application Discontinuation
- 2013-06-19 JP JP2015518539A patent/JP6236439B2/ja not_active Expired - Fee Related
- 2013-06-19 AU AU2013277258A patent/AU2013277258B2/en not_active Ceased
- 2013-06-19 SG SG11201408178TA patent/SG11201408178TA/en unknown
- 2013-06-19 RU RU2014148110A patent/RU2644558C2/ru not_active IP Right Cessation
-
2014
- 2014-11-25 IL IL235909A patent/IL235909A/en active IP Right Grant
- 2014-12-03 ZA ZA2014/08856A patent/ZA201408856B/en unknown
-
2016
- 2016-10-20 US US15/298,469 patent/US9994590B2/en not_active Expired - Fee Related
-
2017
- 2017-09-12 JP JP2017174559A patent/JP6422542B2/ja not_active Expired - Fee Related
-
2018
- 2018-05-11 US US15/977,166 patent/US10604536B2/en active Active
- 2018-10-16 JP JP2018194979A patent/JP6786566B2/ja not_active Expired - Fee Related